Chlorproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2261-2264

  Amukoye, Evans ^a   Winstanley, Peter A ^a,b,c   Watkins, William M ^a,b,c   Snow, Robert W ^a,b   Hatcher, Juanita ^c   Mosobo, Moses ^a   Ngumbao, Edna ^a   Lowe, Brett ^a   Ton, Minh ^c   Minyiri, George ^b   Marsh, Kevin ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL; DAPSONE; FANSIDAR;

ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENTIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PRIORITY JOURNAL;

EID: 0030816523     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2261     Document Type: Article

References (26)

1. Anonymous. 1995. Twelfth programme report of the UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR). World Health Organization, Geneva, Switzerland.
2. Basco, L. K., P. Eldin de Pecoulas, C. M. Wilson, J. Le Bras, and A. Mazabraud. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69:135-138.
3. Bloland, P. B., E. Lackritz, P. Kazembe, J. B. O. Were, R. Steketee, and C. C. Campbell. 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy. J. Infect. Dis. 167: 932-937.
4. Brandling-Bennett, A. D., A. Ollo, W. M. Watkins, D. A. Boriga, D. Kariuki, and W. E. Collins. 1988. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Trans. R. Soc. Trop. Med. Hyg. 82:833-837.
5. Brooks, D. R., P. Wang, M. Read, W. M. Watkins, P. F. Sims, and J. E. Hyde. 1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthetase gene in lines of the human malaria parasite Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224:397-405.
6. Foote, S. J., D. Galatis, and A. F. Cowman. 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 87:3014-3017.
7. Hyde, J. E. 1990. The dihydrofolate-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol. Ther. 48:45-59.
8. Mwenesi, H., T. Harpham, and R. W. Snow. 1995. Child malaria treatment among mothers in Kenya. Soc. Sci. Med. 49:1271-1277.
9. Nevill, C. G., E. S. Some, V. O. Mungala, W. Mutemi, L. New, K. Marsh, C. Lengeler, and R. W. Snow. 1996. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop. Med. Int. Health 1:139-146.
10. Newton, C. R. J. C., P. A. Winstanley, W. M. Watkins, I. N. Mwangi, C. M. Waruiru, E. K. Mberu, N. Peshu, P. A. Warn, and K. Marsh. 1993. Single dose intramuscular pyrimethamine-sulfadoxine as an adjunct to quinine in the treatment of severe malaria: pharmacokinetics and efficacy. Trans. R. Soc. Trop. Med. Hyg. 87:207-210.
11. Patchen, L. C., D. L. Mount, I. K. Schwartz, and F. C. Churchill. 1983. Analysis of filter-paper-absorbed finger-stick blood samples for chloroquine and its major metabolites using high performance liquid chromatography with fluorescence detection. J. Chromatogr. 278:81-89.
12. Peterson, D. S., W. K. Milhous, and T. E. Wellems. 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA 87:3018-3022.
13. Plowe, C. V., A. Djimde, T. E. Wellems, B. Kouriba, and O. K. Doumbo. 1996. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am. J. Trop. Med. Hyg. 55:467-471.
14. Radloff, P. D., J. Phillips, M. Nkeyi, D. Hutchinson, and P. G. Kremsner. 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347:1511-1514.
15. Snewin, V. A., S. M. England, P. F. Sims, and J. E. Hyde. 1989. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene 76:41-52.
16. Snow, R. W., J. R. M. Armstrong, N. Peshu, D. Forster, C. R. J. C. Newton, P. A. Winstanley, I. Mwangi, C. Waruiru, P. A. Warn, C. Newbold, and K. Marsh. 1993. Periodicity and time-space clustering of severe childhood malaria on the Kenyan coast. Trans. R. Soc. Trop. Med. Hyg. 87:386-390.
17. Sudre, P., J. G. Breman, D. McFarland, and J. P. Koplan. 1992. Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis. Int. J. Epidemiol. 21:146-154.
18. Trigg, J. K., H. Mbwana, O. Chambo, E. Hills, J. Curtis, S. Issifou, M. Duraisingh, and C. F. Curtis. 1996. Resistance in Tanzanian Plasmodium falciparum to pyrimethamine-sulfadoxine and a test of chlorproguanil-dapsone. Ann. Trop. Med. Parasitol. 90:408. (Abstract.)
19. Triglia, A., and A. F. Cowman. 1994. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 91:7149-7153.
20. Watkins, W. M., and M. Mosobo. 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine and sulphadoxine: a selective pressure for resistance in a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. 87:75-79.
21. Watkins, W. M., A. D. Brandling-Bennett, C. G. Nevill, J. Y. Carter, D. A. Boriga, R. E. Howells, and D. K. Koech. 1988. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans. R. Soc. Trop. Med. Hyg. 82:398.
22. Watkins, W. M., J. D. Chulay, D. G. Sixsmith, H. C. Spencer, and R. E. Howells. 1987. A preliminary pharmacokinetic study of the antimalarial drugs proguanil and chlorproguanil. J. Pharm. Pharmacol. 39:261-269.
23. Winstanley, P., W. Watkins, D. Muhia, I. S. F. Szwandt, E. Amukoye, and K. Marsh. 1997. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans. R. Soc. Trop. Med. Hyg. 91:322-327.
24. Winstanley, P. A. 1996. Pyronaridine - a promising drug for Africa? Lancet 347:2-3.
25. Winstanley, P. A., W. M. Watkins, C. R. J. C. Newton, C. Nevill, E. Mberu, P. A. Warn, C. M. Waruiru, I. N. Mwangi, D. A. Warrell, and K. Marsh. 1992. The disposition of oral and intramuscular pyrimethamine/sulfadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br. J. Clin. Pharmacol. 33:143-148.
26. Winstanley, P. A., E. K. Mberu, I. S. F. Szwandt, A. M. Breckenridge, and W. M. Watkins. 1995. The in vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob. Agents Chemother. 39:948-952.